Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 6
2005 8
2006 6
2007 12
2008 10
2009 12
2010 18
2011 22
2012 15
2013 20
2014 18
2015 21
2016 19
2017 28
2018 26
2019 41
2020 43
2021 41
2022 54
2023 55
2024 46

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Results by year

Filters applied: . Clear all
Page 1
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Platzbecker U, et al. Among authors: wan y. Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048786 Clinical Trial.
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.
Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, Font P, Diez-Campelo M, Thepot S, Vellenga E, Patnaik MM, Jang JH, Varsos H, Bussolari J, Rose E, Sherman L, Sun L, Wan Y, Dougherty S, Huang F, Feller F, Rizo A, Platzbecker U. Steensma DP, et al. Among authors: wan y. J Clin Oncol. 2021 Jan 1;39(1):48-56. doi: 10.1200/JCO.20.01895. Epub 2020 Oct 27. J Clin Oncol. 2021. PMID: 33108243 Clinical Trial.
Can cysteinyl cathepsin activity control diet-induced NAFLD?
Yu C, Wan Y, Piao L, Wu Cheng X. Yu C, et al. Among authors: wan y. Int J Cardiol Heart Vasc. 2020 Apr 28;28:100516. doi: 10.1016/j.ijcha.2020.100516. eCollection 2020 Jun. Int J Cardiol Heart Vasc. 2020. PMID: 32373709 Free PMC article. No abstract available.
RBM38 in cancer: role and mechanism.
Zou C, Wan Y, He L, Zheng JH, Mei Y, Shi J, Zhang M, Dong Z, Zhang D. Zou C, et al. Among authors: wan y. Cell Mol Life Sci. 2021 Jan;78(1):117-128. doi: 10.1007/s00018-020-03593-w. Epub 2020 Jul 8. Cell Mol Life Sci. 2021. PMID: 32642788 Free PMC article. Review.
Mapping Cell Phenomics with Multiparametric Flow Cytometry Assays.
Liu Y, Zhao H, Fu B, Jiang S, Wang J, Wan Y. Liu Y, et al. Among authors: wan y. Phenomics. 2022 Jan 9;2(4):272-281. doi: 10.1007/s43657-021-00031-0. eCollection 2022 Aug. Phenomics. 2022. PMID: 36939758 Free PMC article. Review.
463 results